A myogenic basis for the overactive bladder

Urology 50, 57-67 DOI: 10.1016/s0090-4295(97)00591-8

Citation Report

#	Article	IF	CITATIONS
1	Discussion: Cellular physiology of detrusor smooth muscle and the development of bladder instability: Possible mechanisms. Urology, 1997, 50, 70-71.	0.5	8
2	Discussion: The neostructural myogenic mechanism of detrusor overactivity. Urology, 1997, 50, 71-73.	0.5	8
3	Discussion: Potential future pharmacologic approaches. Urology, 1997, 50, 87-89.	0.5	63
4	Desensitization of bladder sensory fibers by intravesical capsaicin or capsaicin analogs. A new strategy for treatment of urge incontinence in patients with spinal detrusor hyperreflexia or bladder hypersensitivity disorders. International Urogynecology Journal, 1998, 9, 214-220.	0.7	32
5	PATHOPHYSIOLOGY OF FEMALE LOWER URINARY TRACT DYSFUNCTION. Obstetrics and Gynecology Clinics of North America, 1998, 25, 747-756.	0.7	11
6	The Mechanism of Action of Drugs Affecting the Lower Urinary Tract in the Treatment of Female Urinary Incontinence. The Journal of the British Menopause Society, 1998, 4, 114-121.	1.3	0
7	Effect of Repetitive Stimulation on the Contractile Response of Rabbit Urinary Bladder Subjected to in vitro Hypoxia or in vitro Ischemia Followed by Reoxygenation. Pharmacology, 1998, 57, 139-147.	0.9	51
8	Lower Urinary Tract Function After Intra-arterial Chemotherapy with Concurrent Pelvic Radiotherapy for Invasive Bladder Cancer. Japanese Journal of Clinical Oncology, 1999, 29, 479-484.	0.6	5
9	A Computer Model for Describing the Effect of Urethral Afferents on Simulated Lower Urinary Tract Function. Archives of Physiology and Biochemistry, 1999, 107, 223-235.	1.0	14
10	EFFECTS OF INTRAVESICAL ADMINISTRATION OF THE K + CHANNEL OPENER, ZD6169, IN CONSCIOUS RATS WITH AND WITHOUT BLADDER OUTFLOW OBSTRUCTION. Journal of Urology, 1999, 162, 943-948.	0.2	35
11	OVERACTIVITY AND STRUCTURAL CHANGES IN THE CHRONICALLY ISCHEMIC BLADDER. Journal of Urology, 1999, 162, 1768-1778.	0.2	231
12	DIFFERENTIAL EFFECTS OF SEX HORMONES AND PHYTOESTROGENS ON PEAK AND STEADY STATE CONTRACTIONS IN ISOLATED RABBIT DETRUSOR. Journal of Urology, 1999, 162, 1821-1828.	0.2	34
13	Correlation of EGTA and Calcium- Blocking Agents on the Response of the Bladder to in vitro Ischemia. Pharmacology, 1999, 58, 113-119.	0.9	16
14	MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER. BJU International, 2000, 85, 33-46.	1.3	7
15	Correlation of Intraurethral Ultrasonography and Needle Electromyography of the Urethra. Obstetrics and Gynecology, 2000, 95, 156-159.	1.2	0
16	Comparison of different computer models of the neural control system of the lower urinary tract. Neurourology and Urodynamics, 2000, 19, 289-310.	0.8	13
17	New roles for muscarinic receptors in the pathophysiology of lower urinary tract symptoms. BJU International, 2000, 86, 36-43.	1.3	23
18	The contribution of cholinergic detrusor excitation in a pig model of bladder hypocompliance. BJU International, 2000, 86, 538-543.	1.3	22

#	Article	IF	CITATIONS
19	Drug therapy for urinary incontinence. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2000, 14, 291-313.	1.4	28
20	Pharmacological and molecular analysis of ATP-sensitive K+ channels in the pig and human detrusor. European Journal of Pharmacology, 2000, 400, 287-295.	1.7	63
21	Gastrointestinal tissue as a substitute for the detrusor. World Journal of Urology, 2000, 18, 305-314.	1.2	4
22	Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin. BJU International, 2000, 86, 44-54.	1.3	17
23	Regulation of urinary bladder smooth muscle contractions by ryanodine receptors and BK and SK channels. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R60-R68.	0.9	140
24	Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU International, 2000, 85, 57-68.	1.3	54
25	Ein standardisiertes In-vivo-Modell zur Evaluierung anticholinerger Effekte auf die Blasenkontraktion, den Speichelfluss und auf das Elektromyogramm der Harnblase - A standardized Model for in vivo Investigations of Anticholinergic Effects on Bladder Function, Salivation and Electromyographic Characteristics of the Detrusor C. E. Alken-Preisarbeit 2000 Aktuelle Urologie, 2000, 31, 311-316.	0.3	7
26	Alterations of the Calcium Concentration in Cultured Smooth Muscle Cells of the Lower Urinary Tract following Pharmacological Stimulation. Aktuelle Urologie, 2000, 31, 41-48.	0.3	1
27	Correlation of intraurethral ultrasonography and needle electromyography of the urethra. Obstetrics and Gynecology, 2000, 95, 156-159.	1.2	18
28	Ventral hernia of the urinary bladder with mixed urinary incontinence: treatment with herniorrhaphy and allograft fascial sling. Urology, 2000, 55, 145.	0.5	2
29	Muscarinic receptor antagonists in the treatment of overactive bladder. Urology, 2000, 55, 33-46.	0.5	260
30	CYSTOMETRIC EVALUATION OF BLADDER FUNCTION IN NON-ANESTHETIZED MICE WITH AND WITHOUT BLADDER OUTLET OBSTRUCTION. Journal of Urology, 2000, 164, 1385-1389.	0.2	91
31	DIAGNOSTIC VALUE OF INTRAVESICAL LIDOCAINE FOR OVERACTIVE BLADDER. Journal of Urology, 2000, 164, 340-343.	0.2	75
32	STUDIES OF THE PATHOPHYSIOLOGY OF IDIOPATHIC DETRUSOR INSTABILITY: THE PHYSIOLOGICAL PROPERTIES OF THE DETRUSOR SMOOTH MUSCLE AND ITS PATTERN OF INNERVATION. Journal of Urology, 2000, 163, 646-651.	0.2	182
33	High caffeine consumption was associated with an increased risk of detrusor instability and urge incontinence. Evidence-Based Obstetrics and Gynecology, 2001, 3, 97-98.	0.3	0
34	Bladder instillation of "naked―hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Urology, 2001, 57, 111.	0.5	11
35	Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet, The, 2001, 358, 401-403.	6.3	153
36	EXTERNAL URETHRAL SPHINCTER DILATION FOR THE MANAGEMENT OF HIGH RISK MYELOMENINGOCELE: 15-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 2383-2388.	0.2	30

#	Article	IF	CITATIONS
37	Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opinion on Investigational Drugs, 2001, 10, 65-83.	1.9	55
38	Bladder injection of "naked―hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R1699-R1709.	0.9	66
39	Urge Incontinence and Detrusor Instability. International Urogynecology Journal, 2001, 12, 58-68.	0.7	29
40	Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU International, 2001, 84, 953-960.	1.3	64
41	The pharmacological treatment of urinary incontinence. BJU International, 2001, 84, 923-947.	1.3	141
42	A prospective evaluation of the pathogenesis of detrusor instability in women, using electron microscopy and immunohistochemistry. BJU International, 2001, 86, 970-976.	1.3	19
43	Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats. BJU International, 2001, 87, 256-264.	1.3	27
44	A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU International, 2001, 87, 617-622.	1.3	90
45	Bladder instability: a re-appraisal of classical experimental approaches and development of new therapeutic strategies. Autonomic and Autacoid Pharmacology, 2001, 21, 219-229.	0.7	22
46	Myosin isoforms in female human detrusor. Neurourology and Urodynamics, 2001, 20, 23-29.	0.8	3
47	Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels. British Journal of Pharmacology, 2001, 134, 78-87.	2.7	55
48	β1â€Subunit of the Ca 2+ â€activated K + channel regulates contractile activity of mouse urinary bladder smooth muscle. Journal of Physiology, 2001, 537, 443-452.	1.3	134
49	Origin and propagation of spontaneous excitation in smooth muscle of the guineaâ€pig urinary bladder. Journal of Physiology, 2001, 530, 273-286.	1.3	119
50	Facilitation of transmitter release in the urinary bladders of neonatal and adult rats via α1-adrenoceptors. European Journal of Pharmacology, 2001, 414, 31-35.	1.7	18
51	(â^')-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. II. In Vivo Characterization. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 387-394.	1.3	28
52	(â^')-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. I. In Vitro Characterization. Journal of Pharmacology and Experimental Therapeutics, 2002. 303. 379-386.	1.3	34
55	Pathophysiology of the Overactive Bladder. Clinical Obstetrics and Gynecology, 2002, 45, 182-192.	0.6	16
56	Clinical Aspects of the Overactive Bladder and Detrusor Overactivity. Scandinavian Journal of Urology and Nephrology, 2002, 36, 65-71.	1.4	24

ARTICLE IF CITATIONS # Overactive Bladder-Pharmacological Aspects. Scandinavian Journal of Urology and Nephrology, 2002, 1.4 39 57 36, 72-81. Pathophysiology: the varieties of bladder overactivity. Urology, 2002, 60, 22-26. Current and Future Pharmacological Treatment for Overactive Bladder. Journal of Urology, 2002, 168, 60 0.2 167 1897-1913. The Effect Of Intravesical Resiniferatoxin In Patients With Idiopathic Detrusor Instability Suggests That Involuntary Detrusor Contractions Are Triggered By C-Fiber Input. Journal of Urology, 2002, 168, 148 575-579. P2X RECEPTORS AND THEIR ROLE IN FEMALE IDIOPATHIC DETRUSOR INSTABILITY. Journal of Urology, 2002, 62 0.2 179 167, 157-164. Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 283, R663-R668. Evaluation and treatment of the overactive bladder. Revista Do Hospital Das Clinicas, 2002, 57, 39-48. 64 0.5 28 Botulinum A Toxin and Detrusor Sphincter Dyssynergia: A Double-Blind Lidocaine-Controlled Study in 142 13 Patients with Spinal Cord Disease. European Urology, 2002, 42, 56-62. Detrusor smooth muscle cells of the guinea-pig are functionally coupled via gap junctions in situ and in cell culture. Cell and Tissue Research, 2002, 309, 301-311. 1.5 25 66 Aktuelle M¶glichkeiten zur Rekompensation des Urogenitaltrakts bei QuerschnittlĤmung. Trauma Und Berufskrankheit, 2002, 4, s240-s244. The pharmacological treatment of nocturia. BJU International, 2002, 90, 25-27. 68 1.3 15 Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity 89 to potassium channel modulators. British Journal of Pharmacology, 2002, 135, 639-648. Muscarinic receptors: What we know. Current Urology Reports, 2003, 4, 421-428. 70 1.0 36 Antimuscarinics and the Overactive Detrusor—Which Is the Main Mechanism of Action?. European 251 Urology, 2003, 43, 1-5. Voiding urgency and detrusor contractility in women with overactive bladders. Neurourology and 72 0.8 19 Urodynamics, 2003, 22, 223-226. Clinical pharmacology of old age syndromes. British Journal of Clinical Pharmacology, 2003, 56, 261-272. Innervation of the detrusor muscle bundle in neurogenic detrusor overactivity. BJU International, 74 1.334 2003, 91, 702-710. Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder 1.3 instability in conscious rats with bladder outlet obstruction. BJU International, 2003, 92, 131-136.

		CITATION REPORT		
#	Article		IF	CITATIONS
76	Autonomous Activity in the Isolated Guinea Pig Bladder. Experimental Physiology, 2003	3, 88, 19-30.	0.9	129
77	Agonist- and Nerve-Induced Phasic Activity in the Isolated Whole Bladder of the Guinea for Two types of Bladder Activity. Experimental Physiology, 2003, 88, 343-357.	Pig: Evidence	0.9	75
78	Role of Mitochondria in the Generation of Spontaneous Activity in Detrusor Smooth M Guinea Pig Bladder Journal of Urology, 2003, 170, 628-633.	uscles of the	0.2	17
79	Partial Outlet Obstruction Enhances Modular Autonomous Activity in the Isolated Rat Journal of Urology, 2003, 170, 276-279.	Bladder.	0.2	93
80	Urodynamic Classification of Patients With Symptoms of Overactive Bladder. Journal o 2003, 169, 529-534.	f Urology,	0.2	54
81	Storage and voiding symptoms: pathophysiologic aspects. Urology, 2003, 62, 3-10.		0.5	156
82	Length-dependent regulation of basal myosin phosphorylation and force in detrusor sr American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2 R1063-R1070.	nooth muscle. 003, 284,	0.9	32
83	Recent developments in the management of detrusor overactivity. Current Opinion in 13, 285-291.	Urology, 2003,	0.9	44
84	Nerve regeneration: might this be the only solution for functional problems of the urin Current Opinion in Urology, 2003, 13, 495-500.	ary tract?.	0.9	9
86	Increased connexin43-mediated intercellular communication in a rat model of bladder vivo. American Journal of Physiology - Regulatory Integrative and Comparative Physiolo R1241-R1248.		0.9	98
87	Vesical pacing: pacing parameters required for normalization of vesical electric activity with overactive bladder. Frontiers in Bioscience - Landmark, 2004, 9, 995.	in patients	3.0	4
88	Resiniferatoxin for detrusor instability refractory to anticholinergics. International Braz Official Journal of the Brazilian Society of Urology, 2004, 30, 53-58.	J Urol:	0.7	13
89	The association of diet and other lifestyle factors with the onset of overactive bladder: longitudinal study in men. Public Health Nutrition, 2004, 7, 885-891.	a	1.1	86
90	Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an upd Expert Opinion on Pharmacotherapy, 2004, 5, 2351-2359.	ated review.	0.9	12
91	The M2 muscarinic receptor mediates in vitro bladder contractions from patients with bladder dysfunction. American Journal of Physiology - Regulatory Integrative and Comp Physiology, 2004, 286, R874-R880.	neurogenic parative	0.9	95
92	Modulation of autonomous contractile activity in the isolated whole bladder of the gui International, 2004, 93, 393-400.	nea pig. BJU	1.3	49
93	Noradrenaline inhibits autonomous activity in the isolated guinea pig bladder. BJU Inte 93, 401-409.	rnational, 2004,	1.3	41
94	The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. International, 2004, 93, 478-483.	BJU	1.3	149

#	Article	IF	Citations
95	Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU International, 2004, 94, 817-820.	1.3	236
96	Interstitial cells of the bladder: the missing link?. BJOG: an International Journal of Obstetrics and Gynaecology, 2004, 111, 57-60.	1.1	16
97	In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892. British Journal of Pharmacology, 2004, 143, 81-90.	2.7	7
98	Role of interstitial cells and gap junctions in the transmission of spontaneous Ca2+signals in detrusor smooth muscles of the guinea-pig urinary bladder. Journal of Physiology, 2004, 559, 567-581.	1.3	146
99	Bladder C-Fiber Desensitization Induces a Long-Lasting Improvement of BPH-Associated Storage LUTS: A Pilot Study. European Urology, 2004, 46, 88-94.	0.9	36
100	Increased Expression of Connexin 43 in the Overactive Neurogenic Detrusor. European Urology, 2004, 46, 799-805.	0.9	61
101	Vesical pacing in patients with overactive bladder: Technique and results. International Urology and Nephrology, 2004, 36, 29-34.	0.6	0
102	Synthesis and Structurea 'Activity Relationships of a Novel Series of 2,3,5,6,7,9-Hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide KATPChannel Openers:Â Discovery of (â^')-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637), a Potent KATPOpener That Selectively Inhibits Spontaneous Bladder Contractions. Journal	2.9	45
103	Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 397-400.	1.0	16
105	The electrovesicogram in the overactive bladder: role in determining pathogenesis and diagnostic significance. Urological Research, 2004, 32, 290-293.	1.5	3
106	Gene therapy treatments for erectile and bladder dysfunction. Current Urology Reports, 2004, 5, 52-60.	1.0	16
107	Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs. Neurourology and Urodynamics, 2004, 23, 265-272.	0.8	51
108	Murine in vitro whole bladder model: A method for assessing phenotypic responses to pharmacologic stimuli and hypoxia. Neurourology and Urodynamics, 2004, 23, 349-354.	0.8	5
109	Effects of metabolic stress and ischaemia on the bladder, and the relationship with bladder overactivity. Scandinavian Journal of Urology and Nephrology, 2004, 38, 84-92.	1.4	38
110	Management of Overactive Bladder. New England Journal of Medicine, 2004, 350, 786-799.	13.9	384
111	An appraisal of recently patented compounds for bladder overactivity and urinary incontinence. Expert Opinion on Therapeutic Patents, 2004, 14, 1041-1060.	2.4	3
112	Physiology of incontinence. Clinics in Geriatric Medicine, 2004, 20, 409-425.	1.0	9
113	Rehabilitación de las vejigas neurógenas del adulto. EMC - Kinesiterapia - Medicina FÃsica, 2004, 25, 1-20.	0.1	Ο

	CITATION	CITATION REPORT	
#	Article	IF	Citations
114	Pharmacologic management of urinary incontinence. Clinics in Geriatric Medicine, 2004, 20, 511-523.	1.0	5
116	Drug Treatment of Overactive Bladder. Drugs, 2004, 64, 1643-1656.	4.9	70
117	Comparison of Peripherally Acting Substance for Treatment of Detrusor Overactivity: What is New; What is in the Pipeline?. EAU Update Series, 2004, 2, 161-169.	0.5	10
118	Investigation of the effect of the c-kit inhibitor Glivec on isolated guinea-pig detrusor preparations. Autonomic Neuroscience: Basic and Clinical, 2004, 115, 64-73.	1.4	36
119	(–)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a Novel ATP-Sensitive Potassium Channel Opener: Hemodynamic Comparison to ZD-6169, WAY-133537, and Nifedipine in the Anesthetized Canine. Journal of Cardiovascular Pharmacology, 2004, 44, 137-147.	0.8	14
120	Sacral Neuromodulation in Lower Urinary Tract Dysfunction. Advances and Technical Standards in Neurosurgery, 2005, 30, 177-224.	0.2	15
121	Overactive Bladder. Journal of Wound, Ostomy and Continence Nursing, 2005, 32, S1-S5.	0.6	0
122	Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. BJU International, 2005, 95, 587-590.	1.3	39
123	Loss of ryanodine receptor calcium-release channel expression associated with overactive urinary bladder smooth muscle contractions in a detrusor instability model. BJU International, 2005, 96, 428-433.	1.3	20
124	Overactive bladder. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2005, 19, 829-841.	1.4	18
125	Urgency of micturition and detrusor contractility in men with prostatic obstruction and overactive bladders. Neurourology and Urodynamics, 2005, 24, 202-206.	0.8	3
126	Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 71-78.	1.4	54
127	Mathematical models in urinary system mechanics (review). Fluid Dynamics, 2005, 40, 1-19.	0.2	16
128	Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions. BMC Pharmacology, 2005, 5, 14.	0.4	24
129	The Aging Bladder. , 0, , 1459-1467.		0
130	Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder. American Journal of Physiology - Renal Physiology, 2005, 289, F604-F610.	1.3	78
131	Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1670-1676.	0.9	128
132	Overactive bladder. Perspectives in Public Health, 2005, 125, 176-180.	0.5	3

#	Article	IF	CITATIONS
133	Increased prevalence of interstitial cystitis in women with detrusor overactivity refractory to anticholinergic therapy. Urology, 2005, 66, 702-706.	0.5	42
134	Treatment of overactive bladder syndrome and detrusor overactivity. Reviews in Gynaecological Practice, 2005, 5, 243-250.	0.1	3
135	The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 509-527.	0.9	7
136	Bladder Volume Alters Cholinergic Responses of the Isolated Whole Mouse Bladder. Journal of Urology, 2006, 175, 771-776.	0.2	13
137	When to Use Antimuscarinics in Men Who Have Lower Urinary Tract Symptoms. Urologic Clinics of North America, 2006, 33, 531-537.	0.8	5
138	Pharmacological Management of Women with Mixed Urinary Incontinence. Drugs, 2006, 66, 591-606.	4.9	23
139	The Causes and Consequences of Overactive Bladder. Journal of Women's Health, 2006, 15, 251-260.	1.5	35
140	Effects of Substitution on 9-(3-Bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a Dihydropyridine ATP-Sensitive Potassium Channel Opener. Journal of Medicinal Chemistry, 2006, 49, 6869-6887.	2.9	25
141	Management of Overactive Bladder and Urge Urinary Incontinence in the Elderly Patient. American Journal of Medicine, 2006, 119, 29-36.	0.6	124
142	Non-neuronal cholinergic system in human bladder urothelium. Urology, 2006, 67, 425-430.	0.5	178
143	Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: Potential therapeutic targets for overactive bladder. Urology, 2006, 68, 442-448.	0.5	55
145	Trospium chloride: a different anticholinergic. Expert Review of Obstetrics and Gynecology, 2006, 1, 29-39.	0.4	1
147	Oxybutynin and its New Transdermal Application for the Treatment of Overactive Bladder. Women's Health, 2006, 2, 225-230.	0.7	0
148	Alterations in purinergic and cholinergic components of contractile responses of isolated detrusor contraction in a rat model of partial bladder outlet obstruction. BJU International, 2006, 97, 372-378.	1.3	28
149	Muscarinic stimulation of the rat isolated whole bladder: pathophysiological models of detrusor overactivity. Autonomic and Autacoid Pharmacology, 2006, 26, 261-266.	0.5	21
150	Treatment-resistant detrusor overactivity - underlying pharmacology and potential mechanisms. International Journal of Clinical Practice, 2006, 60, 8-16.	0.8	31
151	Integrated control of lower urinary tract - clinical perspective. British Journal of Pharmacology, 2006, 147, S14-S24.	2.7	87
152	Animal models in urological disease and sexual dysfunction. British Journal of Pharmacology, 2006, 147, S62-S79.	2.7	92

#	Article	IF	CITATIONS
153	Spontaneous activity of lower urinary tract smooth muscles: correlation between ion channels and tissue function. Journal of Physiology, 2006, 570, 13-22.	1.3	147
154	Interaction between interstitial cells and smooth muscles in the lower urinary tract and penis. Journal of Physiology, 2006, 576, 707-714.	1.3	57
155	The puzzle of overactive bladder: controversies, inconsistencies, and insights. International Urogynecology Journal, 2006, 17, 650-658.	0.7	12
156	Inhibitory effects of various L-type and T-type calcium antagonists on electrically generated, potassium-induced and carbachol-induced contractions of porcine detrusor muscle. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2006, 176, 429-439.	0.7	8
159	An update on gene therapy/transfer treatments for bladder dysfunction. Current Bladder Dysfunction Reports, 2006, 1, 119-125.	0.2	8
160	Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs. European Journal of Pharmacology, 2006, 532, 107-114.	1.7	14
161	A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder. European Urology, 2006, 49, 651-659.	0.9	329
162	Comparison study of autonomous activity in bladders from normal and paraplegic rats. Neurourology and Urodynamics, 2006, 25, 368-378.	0.8	19
163	Urgency degree and bladder contraction velocity: Sequential changes in women with idiopathic detrusor overactivity. Neurourology and Urodynamics, 2006, 25, 123-127.	0.8	6
164	Effect of the potassium channel opener WAY-133537 on the overactive bladder of spinalized rats. Neurourology and Urodynamics, 2006, 25, 808-814.	0.8	8
165	Trospium chloride: over 20 years of clinical use. Therapy: Open Access in Clinical Medicine, 2006, 3, 215-226.	0.2	1
166	Pharmacological Treatment for Overactive Bladder in Women. Women's Health, 2006, 2, 239-250.	0.7	0
167	Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age and Ageing, 2006, 35, 16-24.	0.7	127
169	Management of overactive bladder syndrome. Postgraduate Medical Journal, 2007, 83, 481-486.	0.9	35
170	Smooth muscle and neural mechanisms contributing to the downregulation of neonatal rat spontaneous bladder contractions during postnatal development. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R2100-R2112.	0.9	24
171	Changes of gap junctional cell-cell communication in overactive detrusor in rats. American Journal of Physiology - Cell Physiology, 2007, 293, C1627-C1635.	2.1	39
172	Overactive bladder: an update. Current Opinion in Urology, 2007, 17, 231-236.	0.9	78
173	Pelvic floor dysfunction and evidence-based physical therapy. , 2007, , 161-315.		0

#	Article	IF	CITATIONS
174	Structureâ^'Activity Studies of Novel Cyanoguanidine ATP-Sensitive Potassium Channel Openers for the Treatment of Overactive Bladder. Journal of Medicinal Chemistry, 2007, 50, 6265-6273.	2.9	4
175	Relationships Between Micturition Urgency and Involuntary Voiding Dynamics in Men With Urinary Incontinence From Idiopathic Detrusor Overactivity. Journal of Urology, 2007, 178, 563-567.	0.2	6
176	Effects of Tolterodine on Afferent Neurotransmission in Normal and Resiniferatoxin Treated Conscious Rats. Journal of Urology, 2007, 178, 326-331.	0.2	40
177	Oxidative stress reduces the muscarinic receptor function in the urinary bladder. Neurourology and Urodynamics, 2007, 26, 302-308.	0.8	36
178	Changes in T-type calcium channel and its subtypes in overactive detrusor of the rats with partial bladder outflow obstruction. Neurourology and Urodynamics, 2007, 26, 870-878.	0.8	20
179	The extracorporeal perfusion of the female pig detrusor as an experimental model for the study of bladder contractility. Neurourology and Urodynamics, 2007, 26, 1024-1029.	0.8	5
180	Lower urinary tract symptoms (LUTS) and bladder afferent activity. Neurourology and Urodynamics, 2007, 26, 908-913.	0.8	59
181	Characterization of a novel ATP-sensitive K+ channel opener, A-251179, on urinary bladder relaxation and cystometric parameters. British Journal of Pharmacology, 2007, 151, 467-475.	2.7	20
182	Damage to the bladder neck alters autonomous activity and its sensitivity to cholinergic agonists. BJU International, 2007, 100, 919-929.	1.3	21
183	Muscarinic receptor antagonists for overactive bladder. BJU International, 2007, 100, 987-1006.	1.3	339
184	Relaxation of Phasic Contractile Activity of Human Detrusor Strips by Cyclic Nucleotide Phosphodiesterase Type 4 Inhibition. European Urology, 2007, 51, 772-781.	0.9	36
185	A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse. American Journal of Obstetrics and Gynecology, 2007, 197, 82.e1-82.e4.	0.7	77
186	Muscarinic receptors: What we know. Current Bladder Dysfunction Reports, 2007, 2, 29-36.	0.2	0
187	Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia. Current Prostate Reports, 2007, 5, 71-77.	0.1	0
188	Male overactive bladder: The role of urodynamics and anticholinergics. Current Urology Reports, 2007, 8, 66-73.	1.0	6
189	How to choose the initial drug treatment for overactive bladder. Current Urology Reports, 2007, 8, 364-369.	1.0	9
191	Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 437-448.	1.4	123
192	How to choose the initial drug treatment for overactive bladder. Current Bladder Dysfunction Reports, 2008, 3, 41-46.	0.2	0

#	Article	IF	CITATIONS
193	Alternative therapies for overactive bladder: Cannabis and urge incontinence. Current Bladder Dysfunction Reports, 2008, 3, 224-229.	0.2	0
194	Combination antimuscarinics and α-blockers for benign prostatic hyperplasia. Current Urology Reports, 2008, 9, 265-271.	1.0	5
195	Spontaneous activity of mouse detrusor smooth muscle and the effects of the urothelium. Neurourology and Urodynamics, 2008, 27, 79-87.	0.8	55
196	Altered distribution of interstitial cells in the guinea pig bladder following bladder outlet obstruction. Neurourology and Urodynamics, 2008, 27, 330-340.	0.8	64
197	Development of de novo urge incontinence in women post sling: The role of preoperative urodynamics in assessing the risk. Neurourology and Urodynamics, 2008, 27, 407-411.	0.8	36
198	Change in acetylcholine release from rat bladder with partial outlet obstruction. BJU International, 2008, 101, 633-639.	1.3	16
199	The neural control of micturition. Nature Reviews Neuroscience, 2008, 9, 453-466.	4.9	1,171
200	Altered expression of calciumâ€activated K and Cl channels in detrusor overactivity of rats with partial bladder outlet obstruction. BJU International, 2008, 101, 1588-1594.	1.3	31
201	Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats. European Journal of Pharmacology, 2008, 586, 293-299.	1.7	16
202	Physiological and pathological regulation of the autonomic control of urinary bladder contractility. , 2008, 117, 297-312.		79
203	A new method for producing urinary bladder hyperactivity using a non-invasive transient intravesical infusion of acetic acid in conscious rats. Journal of Pharmacological and Toxicological Methods, 2008, 57, 188-193.	0.3	21
204	Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opinion on Emerging Drugs, 2008, 13, 431-446.	1.0	19
205	Trospium 60 mg Once Daily (QD) for Overactive Bladder Syndrome: Results from a Placebo-Controlled Interventional Study. Urology, 2008, 71, 449-454.	0.5	88
206	A pilot study of Connexin 43 (Cx43) in human bladder tissue in patients with idiopathic detrusor overactivity. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 141, 83-86.	0.5	4
207	Pharmacotherapy of overactive bladder syndrome. Expert Review of Clinical Pharmacology, 2008, 1, 163-175.	1.3	1
208	A survey of commonalities relevant to function and dysfunction in pelvic and sexual organs. International Journal of Impotence Research, 2008, 20, 1-16.	1.0	11
209	Basic and Clinical Aspects of Non-neuronal Acetylcholine: Expression of Non-neuronal Acetylcholine in Urothelium and Its Clinical Significance. Journal of Pharmacological Sciences, 2008, 106, 193-198.	1.1	86
210	PHARMACOLOGIC BASIS OF BLADDER AND URETHRAL FUNCTION AND DYSFUNCTION. , 2008, , 47-58.		0

#	Article	IF	CITATIONS
211	Analysis of rhythmic rectal contractions during filling cystometry in women. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2009, 35, 475-483.	0.7	2
212	Bladder-Relaxant Properties of the Novel Benzofuroindole Analogue LDD175. Pharmacology, 2009, 83, 367-378.	0.9	17
213	Basic fibroblast growth factor causes urinary bladder overactivity through gap junction generation in the smooth muscle. American Journal of Physiology - Renal Physiology, 2009, 297, F46-F54.	1.3	34
214	Evaluation of the Differences between the Urodynamic Findings of Neurogenic and Idiopathic Subtypes of Detrusor Overactivity. Current Urology, 2009, 3, 57-61.	0.4	Ο
215	Overactive bladder in males. Therapeutic Advances in Urology, 2009, 1, 209-221.	0.9	17
216	Potential for control of detrusor smooth muscle spontaneous rhythmic contraction by cyclooxygenase products released by interstitial cells of Cajal. Journal of Cellular and Molecular Medicine, 2009, 13, 3236-3250.	1.6	39
217	Aberrant Ca2+ oscillations in smooth muscle cells from overactive human bladders. Cell Calcium, 2009, 45, 456-464.	1.1	37
218	A Refocus on the Bladder as the Originator of Storage Lower Urinary Tract Symptoms: A Systematic Review of the Latest Literature. European Urology, 2009, 56, 810-820.	0.9	107
219	Effects of 17ββâ€estradiol on rat urinary bladder: Gender differences in anoxia–glucopenia and reperfusion damage. Neurourology and Urodynamics, 2009, 28, 535-541.	0.8	7
220	Partial bladder outlet obstruction reduces the tissue antioxidant capacity and muscle nerve density of the guinea pig bladder. Neurourology and Urodynamics, 2009, 28, 461-467.	0.8	18
221	Modification of rat detrusor muscle contraction by ascorbic acid and citric acid involving enhanced neurotransmitter release and Ca ²⁺ influx. Neurourology and Urodynamics, 2009, 28, 542-548.	0.8	10
222	Antimuscarinics and overactive bladder: other mechanism of action. Neurourology and Urodynamics, 2010, 29, 112-115.	0.8	52
224	Mixed incontinence: Do we have the urge to improve the stress?. Current Bladder Dysfunction Reports, 2009, 4, 20-25.	0.2	0
225	The evolving physiology of the lower urinary tract: What we are learning and where we need to go. Current Bladder Dysfunction Reports, 2009, 4, 81-85.	0.2	0
227	Urinary levels of glycosaminoglycans in patients with idiopathic detrusor overactivity. International Urogynecology Journal, 2009, 20, 1477-1480.	0.7	10
228	Perspectives on overactive bladder in the elderly population. World Journal of Urology, 2009, 27, 729-737.	1.2	11
229	Effects of 17βâ€oestradiol on rat detrusor smooth muscle contractility. Experimental Physiology, 2009, 94, 834-846.	0.9	11
230	Urinary urgency - translating the evidence base into daily clinical practice. International Journal of Clinical Practice, 2009, 63, 1675-1682.	0.8	11

щ	Article	IF	Citations
# 231	<pre><i>In vivo</i> and <i>in vitro</i> pharmacological characterization of SVTâ€40776, a novel M₃ muscarinic receptor antagonist, for the treatment of overactive bladder. British</pre>	ıг 2.7	17
201	Journal of Pharmacology, 2009, 156, 807-817.	2.7	17
232	Spontaneous release of acetylcholine from autonomic nerves in the bladder. British Journal of Pharmacology, 2009, 157, 607-619.	2.7	31
233	Role of K ⁺ Channels in Regulating Spontaneous Activity in Detrusor Smooth Muscle In Situ in the Mouse Bladder. Journal of Urology, 2009, 181, 2355-2365.	0.2	38
234	Preclinical compounds for the treatment of overactive bladder. Expert Opinion on Therapeutic Patents, 2009, 19, 107-117.	2.4	0
235	Bladder Sensation Measures and Overactive Bladder. Journal of Urology, 2009, 182, 1050-1054.	0.2	7
236	Pathophysiology of Urinary Incontinence, Voiding Dysfunction, and Overactive Bladder. Obstetrics and Gynecology Clinics of North America, 2009, 36, 463-474.	0.7	13
237	Rhythmic contraction generates adjustable passive stiffness in rabbit detrusor. Journal of Applied Physiology, 2010, 108, 544-553.	1.2	18
238	Is the beneficial effect of antimuscarinics related to motor or sensory changes in the bladder?. International Urogynecology Journal, 2010, 21, 841-845.	0.7	18
239	COX Inhibitors and Overactive Bladder: The Potential for Future Therapy. Current Bladder Dysfunction Reports, 2010, 5, 4-12.	0.2	1
240	Urodynamics in the Evaluation of Overactive Bladder. Current Urology Reports, 2010, 11, 343-347.	1.0	33
241	Physiopathologie de l'hyperactivité vésicale. Lettre De Medecine Physique Et De Readaptation, 2010, 26, 69-73.	0.1	2
242	Detrusor myocyte activity and afferent signaling. Neurourology and Urodynamics, 2010, 29, 97-106.	0.8	89
243	Effects of anterior trocar guided transvaginal mesh surgery on lower urinary tract symptoms. Neurourology and Urodynamics, 2010, 29, 1419-1423.	0.8	16
244	Update on the management of overactive bladder: patient considerations and adherence. Research and Reports in Urology, 2010, Volume 3, 7-17.	0.6	0
245	Update on the management of overactive bladder: patient considerations and adherence. Open Access Journal of Urology, 2010, 3, 7.	0.3	6
246	The Scientific Basis of Urology. , 0, , .		18
247	The overactive bladder. Therapeutic Advances in Urology, 2010, 2, 147-155.	0.9	13
248	BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 298, R378-R384.	0.9	48

#	Article	IF	CITATIONS
249	New insights into molecular targets for urinary incontinence. Indian Journal of Pharmacology, 2010, 42, 261.	0.4	3
250	Bladder Afferent Signaling: Recent Findings. Journal of Urology, 2010, 183, 1288-1295.	0.2	146
251	A noninvasive evaluation of autonomic nervous system dysfunction in women with an overactive bladder. International Journal of Gynecology and Obstetrics, 2010, 110, 12-17.	1.0	23
252	Effects of Mechanical Stretch on Interstitial Cells of Cajal in Guinea Pig Bladder. Journal of Surgical Research, 2010, 164, e213-e219.	0.8	26
253	Fesoterodine for overactive bladder: A review of the literature. Current Therapeutic Research, 2010, 71, 273-288.	0.5	7
254	The medical management of urinary incontinence. Autonomic Neuroscience: Basic and Clinical, 2010, 152, 4-10.	1.4	25
255	The physiological function of lower urinary tract smooth muscle. Autonomic Neuroscience: Basic and Clinical, 2010, 154, 3-13.	1.4	79
256	New Concepts and Pathophysiology of Lower Urinary Tract Symptoms in Men. European Urology Supplements, 2010, 9, 472-476.	0.1	13
257	Hyperosmolarity alters micturition: a comparison of urinary bladder motor activity in hyperosmolar and cyclophosphamide-induced models of overactive bladder. Canadian Journal of Physiology and Pharmacology, 2010, 88, 899-906.	0.7	14
258	From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. Nature Reviews Urology, 2011, 8, 617-630.	1.9	52
259	Physiology and Pharmacology of the Bladder. , 2011, , 123-138.		0
260	Pathophysiological Studies of Overactive Bladder and Bladder Motor Dysfunction in a Rat Model of Metabolic Syndrome. Journal of Urology, 2011, 186, 318-325.	0.2	36
261	OAB Update: Focus on Trospium. Clinical Medicine Insights Urology, 2011, 5, CMU.S5068.	0.4	0
262	Overactive Bladder: Pathophysiology, Diagnostics, and Therapies. Advances in Urology, 2011, 2011, 1-1.	0.6	5
263	Understanding stress urinary incontinence. Nurse Practitioner, 2011, 36, 24-36.	0.2	8
264	Influence of age and bladder dysfunction on the contractile properties of isolated human detrusor smooth muscle. BJU International, 2011, 108, E91-6.	1.3	51
265	Large conductance Ca2+-activated K+ channel activation with NS1619 decreases myogenic and neurogenic contractions of rat detrusor smooth muscle. European Journal of Pharmacology, 2011, 670, 252-259.	1.7	36
266	Afferent Mechanism in the Urinary Tract. Handbook of Experimental Pharmacology, 2011, , 171-205.	0.9	35

#	Article	IF	CITATIONS
267	The role of urgency, frequency, and nocturia in defining overactive bladder adaptive behavior. Neurourology and Urodynamics, 2011, 30, 406-411.	0.8	9
268	Sophisticated models and methods for studying neurogenic bladder dysfunction. Neurourology and Urodynamics, 2011, 30, 658-667.	0.8	18
269	Distribution of interstitial cells of cajal and expression of nitric oxide synthase after experimental bladder outlet obstruction in a rat model of bladder overactivity. Neurourology and Urodynamics, 2011, 30, 1639-1645.	0.8	37
271	Role of KIT-Positive Interstitial Cells of Cajal in the Urinary Bladder and Possible Therapeutic Target for Overactive Bladder. Advances in Urology, 2011, 2011, 1-7.	0.6	29
272	Adjustable passive stiffness in mouse bladder: regulated by Rho kinase and elevated following partial bladder outlet obstruction. American Journal of Physiology - Renal Physiology, 2012, 302, F967-F976.	1.3	12
273	Antimuscarinic drugs to treat overactive bladder. BMJ: British Medical Journal, 2012, 344, e2130-e2130.	2.4	28
274	The management of overactive bladder syndrome. BMJ, The, 2012, 344, e2365-e2365.	3.0	49
275	Alfuzosin for the treatment of storage symptoms suggestive of overactive bladder. Expert Opinion on Pharmacotherapy, 2012, 13, 1143-1151.	0.9	2
276	Modulation of spontaneous activity in the overactive bladder: the role of P2Y agonists. American Journal of Physiology - Renal Physiology, 2012, 302, F1447-F1454.	1.3	43
277	Neurogenic Lower Urinary Tract Dysfunction—Do We Need Same Session Repeat Urodynamic Investigations?. Journal of Urology, 2012, 187, 1318-1323.	0.2	26
278	Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips—A pharmacological study towards a new treatment option of overactive bladder. Phytomedicine, 2012, 19, 947-951.	2.3	24
279	Classification and analysis of electrical signals in urinary bladder smooth muscle using a modified vector quantization technique. , 2012, , .		8
280	Effects of kinin <scp>B</scp> ₁ and <scp>B</scp> ₂ receptor antagonists on overactive urinary bladder syndrome induced by spinal cord injury in rats. British Journal of Pharmacology, 2012, 167, 1737-1752.	2.7	19
281	Changes in detrusor muscle oxygenation during detrusor overactivity contractions. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 163, 104-107.	0.5	10
282	Altered Caveolar Mediated Purinergic Signaling in Spontaneously Hypertensive Rats with Detrusor Overactivity. Journal of Urology, 2012, 188, 1017-1026.	0.2	12
285	Characterization of Gap Junction Proteins in the Bladder of Cx43 Mutant Mouse Models of Oculodentodigital Dysplasia. Journal of Membrane Biology, 2012, 245, 345-355.	1.0	14
286	Is a sequence of tests during urethral pressure profilometry correlated with symptoms assessment in women?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2012, 38, 809-817.	0.7	3
287	Survey on the Prevalence of Overactive Bladder in Healthy Korean Postmenopausal Women. The Journal of Korean Society of Menopause, 2012, 18, 60.	0.6	5

#	Article	IF	CITATIONS
288	Neuronalâ€derived nitric oxide modulates the activity of mouse detrusor smooth muscle. Neurourology and Urodynamics, 2012, 31, 572-578.	0.8	5
289	Pathophysiology of overactive bladder. International Urogynecology Journal, 2012, 23, 975-982.	0.7	78
290	Realâ€ŧime magnetic resonance imaging (MRI): anatomical changes during physiological voiding in men. BJU International, 2012, 109, 234-239.	1.3	28
291	Spontaneous Contractile Activity of the Detrusor Muscle and Its Role in the Pathogenesis of Overactive Bladder Syndrome. LUTS: Lower Urinary Tract Symptoms, 2012, 4, 42-47.	0.6	5
292	Pathophysiology of Overactive Bladder. LUTS: Lower Urinary Tract Symptoms, 2012, 4, 48-55.	0.6	49
293	Detrusor Overactivity in Hyperchoelsterolemia Rats. LUTS: Lower Urinary Tract Symptoms, 2012, 4, 16-20.	0.6	2
294	Effect of silymarin on bladder overactivity in cyclophosphamide-induced cystitis rat model. Phytomedicine, 2012, 19, 840-845.	2.3	10
295	Oxybutynin: past, present, and future. International Urogynecology Journal, 2013, 24, 595-604.	0.7	30
296	Effects of Vitamin D Analog on Bladder Function and Sensory Signaling in Animal Models of Cystitis. Urology, 2013, 81, 466.e1-466.e7.	0.5	10
297	Understanding Clinic Options for Overactive Bladder. Current Urology Reports, 2013, 14, 541-548.	1.0	21
298	Obesity and the Overactive Bladder. Current Bladder Dysfunction Reports, 2013, 8, 62-68.	0.2	6
299	Randomized, double-blind placebo-controlled trial with Bryophyllum pinnatum versus placebo for the treatment of overactive bladder in postmenopausal women. Phytomedicine, 2013, 20, 351-358.	2.3	28
300	Fourier Transform Analysis of Rabbit Detrusor Autonomous Contractions Reveals Length Dependent Increases in Tone and Slow Wave Development at Long Lengths. Journal of Urology, 2013, 190, 334-340.	0.2	12
301	Involvement of Connexins 43 and 45 in Functional Mechanism of Human Detrusor Overactivity in Neurogenic Bladder. Urology, 2013, 81, 1108.e1-1108.e6.	0.5	12
302	Principios de acción e indicaciones de la toxina botulÃnica en el tratamiento de la hiperactividad vesical del adulto. EMC - UrologÃa, 2013, 45, 1-12.	0.0	0
303	Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action. International Journal of Urology, 2013, 20, 28-39.	0.5	47
304	Myocardin and microRNAâ€1 modulate bladder activity through connexin 43 expression during postâ€natal development. Journal of Cellular Physiology, 2013, 228, 1819-1826.	2.0	24
305	Sex Differences in the Physiology and Pharmacology of the Lower Urinary Tract. Current Urology, 2013, 6, 179-188.	0.4	35

#ARTICLEIFCITATIONS306THTP IS Endogenous Relaxant for Spontaneous Smooth Muscle Contraction in Urinary Bladder of
Female Rat. Endogring, 2013, 154, 2058-2068.1.412307Three-dimensional effects in the lower urinary tract. IMA Journal of Applied Mathematics, 2013, 780.88

CITATION REPORT

308 New developments in the diagnosis and management of overactive bladder. Clinical Practice (London,) Tj ETQq0 0 0 orgBT /Overlock 10 T

309	New therapies in the treatment of overactive bladder. Expert Opinion on Emerging Drugs, 2013, 18, 319-337.	1.0	10
310	Neurogenic Detrusor Overactivity Is Associated with Decreased Expression and Function of the Large Conductance Voltage- and Ca2+-Activated K+ Channels. PLoS ONE, 2013, 8, e68052.	1.1	45
312	Improved model for the establishment and evaluation of detrusor overactivity in female Wistar rats. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 414-422.	0.7	9
313	BK channel activators and their therapeutic perspectives. Frontiers in Physiology, 2014, 5, 389.	1.3	120
314	Evidence for Bladder Urothelial Pathophysiology in Functional Bladder Disorders. BioMed Research International, 2014, 2014, 1-15.	0.9	71
315	Alterations of the Myovesical Plexus of the Human Overactive Detrusor. BioMed Research International, 2014, 2014, 1-8.	0.9	3
316	Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "Overactive bladder― Neurourology and Urodynamics, 2014, 33, S6-13.	0.8	47
317	Urinary Incontinence in the Young Woman: Treatment Plans and Options Available. Women's Health, 2014, 10, 201-217.	0.7	11
318	Oestrogens and overactive bladder. Neurourology and Urodynamics, 2014, 33, 1086-1091.	0.8	65
319	A new and automated method for objective analysis of detrusor rhythm during the filling phase. World Journal of Urology, 2014, 32, 85-90.	1.2	2
320	The Effectiveness of Bladder Training in Overactive Bladder. Current Bladder Dysfunction Reports, 2014, 9, 63-70.	0.2	5
321	Effects of Rhoâ€kinase inhibition on myosin light chain phosphorylation and obstructionâ€induced detrusor overactivity. International Journal of Urology, 2014, 21, 319-324.	0.5	6
322	NS19504: A Novel BK Channel Activator with Relaxing Effect on Bladder Smooth Muscle Spontaneous Phasic Contractions. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 520-530.	1.3	29
324	Important drug–drug interactions for treatments that target overactive bladder syndrome. International Urogynecology Journal, 2014, 25, 715-720.	0.7	4
328	Enhanced expression of TWIK-related arachidonic acid-activated K+ channel in the spinal cord of detrusor overactivity rats after partial bladder outlet obstruction. BMC Urology, 2015, 15, 100.	0.6	3

#	Article	IF	CITATIONS
330	Associations between individual lower urinary tract symptoms and bacteriuria in random urine samples in women. Neurourology and Urodynamics, 2015, 34, 429-433.	0.8	19
331	Characterisation of the contractile dynamics of the resting <i>exÂvivo</i> urinary bladder of the pig. BJU International, 2015, 116, 973-983.	1.3	28
333	Overactive bladder. F1000Research, 2015, 4, 1406.	0.8	12
334	Urinary Retention, Incontinence, and Dysregulation of Muscarinic Receptors in Male Mice Lacking Mras. PLoS ONE, 2015, 10, e0141493.	1.1	9
335	Improvement of overactive bladder symptoms after tensionâ€free vaginal mesh operation in women with pelvic organ prolapse: Correlation with preoperative urodynamic findings. International Journal of Urology, 2015, 22, 577-580.	0.5	15
336	Anatomy and physiology of the lower urinary tract. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 130, 61-108.	1.0	113
337	Protein kinase C modulates frequency of micturition and non-voiding contractions in the urinary bladder via neuronal and myogenic mechanisms. BMC Urology, 2015, 15, 34.	0.6	8
338	Spatiotemporal dynamics of synaptic drive in urinary bladder syncytium: A computational investigation. , 2015, 2015, 8074-7.		2
339	Conscious voiding during bladder obstruction in guinea pigs correlates with contractile activity of isolated bladders. Autonomic Neuroscience: Basic and Clinical, 2015, 193, 74-83.	1.4	2
340	Physiological and pathophysiological implications of micromotion activity in urinary bladder function. Acta Physiologica, 2015, 213, 360-370.	1.8	39
341	Evaluation of mouse urinary bladder smooth muscle for diurnal differences in contractile properties. Frontiers in Pharmacology, 2014, 5, 293.	1.6	15
342	Research Findings on Overactive Bladder. Current Urology, 2015, 8, 1-21.	0.4	25
344	Intracellular Bacterial Communities: A Potential Etiology for Chronic Lower Urinary Tract Symptoms. Urology, 2015, 86, 425-431.	0.5	73
345	A computational model of urinary bladder smooth muscle syncytium. Journal of Computational Neuroscience, 2015, 38, 167-187.	0.6	25
346	Original Research: Combined model of bladder detrusor smooth muscle and interstitial cells. Experimental Biology and Medicine, 2016, 241, 1853-1864.	1.1	4
347	β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. , 2016, 159, 66-82.		52
348	Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review. International Urogynecology Journal, 2016, 27, 1633-1644.	0.7	3
349	Effects of K + channel openers on spontaneous action potentials in detrusor smooth muscle of the guinea-pig urinary bladder. European Journal of Pharmacology, 2016, 789, 179-186.	1.7	15

#	Article	IF	CITATIONS
350	Overactive bladder in women. Nursing Standard (Royal College of Nursing (Great Britain): 1987), 2016, 31, 52-63.	0.1	4
351	The actions of isoprenaline and mirabegron in the isolated whole rat and guinea pig bladder. Autonomic Neuroscience: Basic and Clinical, 2016, 198, 19-27.	1.4	2
352	Transient contractions of urinary bladder smooth muscle are drivers of afferent nerve activity during filling. Journal of General Physiology, 2016, 147, 323-335.	0.9	56
353	Pathophysiology of Overactive Bladder: Current Understanding. Current Bladder Dysfunction Reports, 2017, 12, 74-79.	0.2	9
354	Finding NeMO—Nerve-sparing Mid-urethral Obstruction: A Pathophysiologically Accurate Model of Rodent Partial Bladder Outlet Obstruction. Urology, 2017, 105, 208.e1-208.e9.	0.5	8
355	The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation. Urologia Internationalis, 2017, 99, 51-55.	0.6	5
356	Spatiotemporal analysis of spontaneous myogenic contractions in the urinary bladder of the rabbit: timing and patterns reflect reported electrophysiology. American Journal of Physiology - Renal Physiology, 2017, 313, F687-F698.	1.3	15
357	Incontinence and Nocturia in Older Adults After Hip Fracture: Analysis of a Secondary Outcome for a Parallel Group, Randomized Controlled Trial. Gerontology and Geriatric Medicine, 2017, 3, 233372141770957.	0.8	6
358	Urinary Metabolic Phenotyping of Women with Lower Urinary Tract Symptoms. Journal of Proteome Research, 2017, 16, 4208-4216.	1.8	13
359	Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction. Scientific Reports, 2017, 7, 7646.	1.6	17
360	Effects of tai chi on symptoms and quality of life in women with overactive bladder symptoms: A non-randomized clinical trial. European Journal of Integrative Medicine, 2017, 12, 189-195.	0.8	2
361	Partial bladder outlet obstruction is associated with decreased expression and function of the small-conductance Ca2+-activated K+ channel in guinea pig detrusor smooth muscle. International Urology and Nephrology, 2017, 49, 17-26.	0.6	8
362	A Method for the Analysis of AP Foot Convexity: Insights into Smooth Muscle Biophysics. Frontiers in Bioengineering and Biotechnology, 2017, 5, 64.	2.0	2
363	Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate. Scientific Reports, 2017, 7, 10150.	1.6	7
364	Effects of nitric oxide inhibitors in mice with bladder outlet obstruction. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 356-366.	0.7	6
365	Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction. Neurourology and Urodynamics, 2018, 37, 1897-1903.	0.8	8
366	Adult and Pediatric Neuromodulation. , 2018, , .		2
367	Proteomic Analysis of Urothelium of Rats with Detrusor Overactivity Induced by Bladder Outlet Obstruction. Molecular and Cellular Proteomics, 2018, 17, 948-960.	2.5	8

#	Article	IF	CITATIONS
368	Is there "brain OAB―and how can we recognize it? International Consultation on Incontinenceâ€Research Society (ICIâ€RS) 2017. Neurourology and Urodynamics, 2018, 37, S38-S45.	0.8	13
369	Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. , 2018, 189, 130-148.		68
370	Effect of pregnancy on cooling tone and rhythmic contractions of the rat urinary bladder. International Urology and Nephrology, 2018, 50, 833-838.	0.6	1
371	Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placeboâ€controlled, doubleâ€blind, parallel group study. Neurourology and Urodynamics, 2018, 37, 237-243.	0.8	7
372	Benefits and limitations of animal models in partial bladder outlet obstruction for translational research. International Journal of Urology, 2018, 25, 36-44.	0.5	35
373	Animal Models of Double Incontinence: "Fecal and Urinaryâ€, , 2018, , .		Ο
374	Shared Pathophysiology of Detrusor Overactivity and Detrusor Underactivity. Current Bladder Dysfunction Reports, 2018, 13, 267-273.	0.2	1
375	Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Therapeutic Advances in Urology, 2018, 10, 411-419.	0.9	12
376	PATHOPHYSIOLOGY, MECHANISM AND MANAGEMENT OF OVERACTIVE BLADDER SYNDROME-A REVIEW. International Journal of Pharmacy and Pharmaceutical Sciences, 2018, 10, 1.	0.3	0
377	Urinary Urgency in the Elderly. Gerontology, 2018, 64, 541-550.	1.4	8
378	Investigation of the Syncytial Nature of Detrusor Smooth Muscle as a Determinant of Action Potential Shape. Frontiers in Physiology, 2018, 9, 1300.	1.3	6
379	Lower Urinary Tract Symptoms in Subjects with Subclinical Cerebral White Matter Lesions. Journal of Aging Research, 2018, 2018, 1-5.	0.4	6
380	Effects of caveolae depletion and urothelial denudation on purinergic and cholinergic signaling in healthy and cyclophosphamide-induced cystitis in the rat bladder. Autonomic Neuroscience: Basic and Clinical, 2018, 213, 60-70.	1.4	7
381	Position statement: a clinical approach to the management of adult nonâ€neurogenic overactive bladder. Medical Journal of Australia, 2018, 208, 41-45.	0.8	11
382	Regulation of Spontaneous Contractions in Intact Rat Bladder Strips and the Effects of Hydrogen Peroxide. BioMed Research International, 2018, 2018, 1-9.	0.9	4
383	The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy. Therapeutic Advances in Urology, 2018, 10, 243-256.	0.9	9
384	Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory) Tj ETQq0 0 0 rg	BT /Overlc	ock 10 Tf 50 1

385	Automated quantification of low amplitude rhythmic contractions (LARC) during real-world urodynamics identifies a potential detrusor overactivity subgroup. PLoS ONE, 2018, 13, e0201594.	1.1	12
-----	---	-----	----

#	Article	IF	CITATIONS
386	What happens to urinary incontinence after pelvic organ prolapse surgery?. International Urogynecology Journal, 2019, 30, 1147-1152.	0.7	9
387	Management of Overactive Bladder After Treatment of Bladder Outlet Obstruction. Current Bladder Dysfunction Reports, 2019, 14, 197-204.	0.2	1
388	Is nocturnal enuresis a predisposing factor for the overactive bladder?. Turkish Journal of Medical Sciences, 2019, 49, 703-709.	0.4	1
389	Spontaneous synaptic drive in detrusor smooth muscle: computational investigation and implications for urinary bladder function. Journal of Computational Neuroscience, 2019, 47, 167-189.	0.6	2
391	Functional changes in low- and high-threshold afferents in obstruction-induced bladder overactivity. American Journal of Physiology - Renal Physiology, 2019, 316, F1103-F1113.	1.3	7
392	New Diagnostics for Male Lower Urinary Tract Symptoms. Current Bladder Dysfunction Reports, 2019, 14, 90-97.	0.2	4
393	Effect of high-fat diet-induced obesity on the small-conductance Ca2+-activated K+ channel function affecting the contractility of rat detrusor smooth muscle. International Urology and Nephrology, 2019, 51, 61-72.	0.6	4
394	Moving beyond BPH – A contemporary update on male LUTS. Asian Journal of Urology, 2019, 6, 208-209.	0.5	0
395	Contractile elements and their sympathetic regulations in the pig urinary bladder: a species and regional comparative study. Cell and Tissue Research, 2020, 379, 373-387.	1.5	14
396	The intracellular Ca ²⁺ release channel TRPML1 regulates lower urinary tract smooth muscle contractility. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30775-30786.	3.3	13
397	Lower urinary tract dysfunction in adult patients with mitochondrial disease. Neurourology and Urodynamics, 2020, 39, 2253-2263.	0.8	5
399	>Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient. Clinical Interventions in Aging, 2020, Volume 15, 575-581.	1.3	11
400	The clinical pharmacology of the medical treatment for overactive bladder in adults. Expert Review of Clinical Pharmacology, 2020, 13, 707-720.	1.3	8
401	Overactive bladder syndrome – focus onto detrusor overactivity. Scandinavian Journal of Urology, 2021, 55, 56-60.	0.6	5
402	Physiopathology of Overactive Bladder. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , 1-11.	0.0	0
403	Bladder Outlet Obstruction and Overactive Bladder in Males. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , 67-85.	0.0	1
404	Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review. Pharmaceuticals, 2021, 14, 409.	1.7	14
405	Comparison of Pelvic Floor Muscle Training With Connective Tissue Massage to Pelvic Floor Muscle Training Alone in Women With Overactive Bladder: A Randomized Controlled Study. Journal of Manipulative and Physiological Therapeutics, 2021, 44, 295-306.	0.4	2

#	Article	IF	CITATIONS
406	Nerve transfer for restoration of lower motor neuron-lesioned bladder function. Part 1: attenuation of purinergic bladder smooth muscle contractions. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 320, R885-R896.	0.9	7
407	Chronic psychological stress and lower urinary tract symptoms. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 414-424.	0.6	27
408	Overactive Bladder: Where We Are and Where We Are Going. Société Internationale D'urologie Journal, 2021, , 311-322.	0.2	0
409	Native tissue repair of cardinal/uterosacral ligaments cures overactive bladder and prolapse, but only in pre-menopausal women. Central European Journal of Urology, 2021, 74, 372-378.	0.2	12
410	Intercellular Communication and Bladder Function. , 2003, 539, 239-254.		8
411	Ultrastructural Diagnosis of Neuropathic Detrusor Overactivity: Validation of a Common Myogenic Mechanism. , 2003, 539, 281-291.		6
412	Animal Models in Overactive Bladder Research. Handbook of Experimental Pharmacology, 2011, , 15-43.	0.9	59
413	Physiology and Pharmacology of the Bladder and Urethra. , 2012, , 1786-1833.e17.		22
414	Overactive Bladder. , 2012, , 1947-1957.e2.		5
415	Non-Neuropathic Dysfunction of the Lower Urinary Tract in Children. , 2012, , 3411-3430.e3.		1
416	The overactive bladder: neuropharmacological basis of clinical management. Current Opinion in Obstetrics and Gynecology, 1999, 11, 477-483.	0.9	2
417	OVERACTIVITY AND STRUCTURAL CHANGES IN THE CHRONICALLY ISCHEMIC BLADDER. Journal of Urology, 1999, , 1768.	0.2	8
418	STUDIES OF THE PATHOPHYSIOLOGY OF IDIOPATHIC DETRUSOR INSTABILITY:. Journal of Urology, 2000, , 646.	0.2	4
419	DIAGNOSTIC VALUE OF INTRAVESICAL LIDOCAINE FOR OVERACTIVE BLADDER. Journal of Urology, 2000, , 340-343.	0.2	4
420	EXTERNAL URETHRAL SPHINCTER DILATION FOR THE MANAGEMENT OF HIGH RISK MYELOMENINGOCELE: 15-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 2383-2388.	0.2	10
421	P2X RECEPTORS AND THEIR ROLE IN FEMALE IDIOPATHIC DETRUSOR INSTABILITY. Journal of Urology, 2002, , 157-164.	0.2	4
422	The Effect Of Intravesical Resiniferatoxin In Patients With Idiopathic Detrusor Instability Suggests That Involuntary Detrusor Contractions Are Triggered By C-Fiber Input. Journal of Urology, 2002, , 575-579.	0.2	8
423	Current and Future Pharmacological Treatment for Overactive Bladder. Journal of Urology, 2002, , 1897-1913.	0.2	7

#	Article	IF	CITATIONS
424	Overactive detrusor. Current Opinion in Urology, 1999, 9, 291-296.	0.9	2
425	Urinary bladder instability induced by selective suppression of the murine small conductance calcium-activated potassium (SK3) channel. Journal of Physiology, 2003, 551, 893-903.	1.3	112
426	Increased Expression of TREK-1 K+ Channel in the Dorsal Root Ganglion of Rats with Detrusor Overactivity After Partial Bladder Outlet Obstruction. Medical Science Monitor, 2018, 24, 1064-1071.	0.5	6
427	Alterations in Nerve-Evoked Bladder Contractions in a Coronavirus-Induced Mouse Model of Multiple Sclerosis. PLoS ONE, 2014, 9, e109314.	1.1	9
428	The Ameliorating Effect of Exogenous Melatonin on Urinary Bladder Function in Hyperosmolar Bladder Overactivity and its Influence on the Autonomic Nervous System Activity. Acta Medica (Hradec) Tj ETQq() 0002rgBT	/Osverlock 10
429	Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Technology Assessment, 2016, 20, 1-150.	1.3	25
430	Medical management of overactive bladder. Indian Journal of Urology, 2010, 26, 270.	0.2	12
431	Overactive Bladder. Korean Journal of Urology, 2007, 48, 1191.	0.2	16
432	Distribution of interstitial cells of Cajal in the bladders of fetal rats with retinoic acid induced myelomeningocele. Turkish Journal of Urology, 2016, 42, 285-289.	1.3	6
433	Treatment of mixed urinary incontinence. Central European Journal of Urology, 2011, 64, 120-126.	0.2	12
434	Cajal–like interstitial cells as a novel target in detrusor overactivity treatment: true or myth?. Central European Journal of Urology, 2013, 66, 413-7.	0.2	21
435	Prevalence of Spina Bifida Occulta and Its Relationship With Overactive Bladder in Middle-Aged and Elderly Chinese People. International Neurourology Journal, 2016, 20, 151-158.	0.5	13
436	Intravesical PGE2 Administration in Conscious Rats as an Experimental Model of Detrusor Overactivity Observed by Simultaneous Registrations of Intravesical and Intraabdominal Pressures. International Neurourology Journal, 2010, 14, 69.	0.5	3
437	Development and Changes with Age of Detrusor Overactivity in Spontaneous Hypertensive Rats as Observed by Simultaneous Registrations of Intravesical and Intraabdominal Pressures. International Neurourology Journal, 2011, 15, 192.	0.5	10

0

0

442	Treatment options for the overactive bladder syndrome. Therapy: Open Access in Clinical Medicine, 2005, 2, 921-936.	0.2	0
-----	---	-----	---

439

441

Bladder., 2003,, 323-333.

Muscarinic receptors and the aging bladder. , 2004, , 41-51.

Spezielle Urodynamik der Frau. , 2004, , 159-170.

#	Article	IF	Citations
443	Treatment options for the overactive bladderÂsyndrome. Therapy: Open Access in Clinical Medicine, 2005, 2, 921-936.	0.2	0
444	GYNAECOLOGICAL CONDITIONS RELEVANT TO THE COLORECTAL SURGEON. , 2008, , 2383-2414.		0
445	Urodynamische Evaluation der Inkontinenz. , 2009, , 31-36.		3
446	Application and Limitations of Awake Cystometry in Sprague-Dawley Rats with Partial Bladder Outlet Obstruction as a Model of Overactive Bladder or Obstruction. Korean Journal of Urology, 2009, 50, 486.	1.2	4
447	Pathophysiologie der Harninkontinenz und des Deszensus. , 2009, , 9-13.		0
450	Spezielle Urodynamik der Frau. , 2012, , 185-198.		4
451	Other Varieties of Dysfunction. Current Clinical Urology, 2014, , 65-73.	0.0	0
452	Dysfunction in Anatomic Outlet Obstruction in Men. Current Clinical Urology, 2014, , 37-50.	0.0	0
454	Urodynamische Evaluation der Inkontinenz. , 2015, , 37-43.		1
456	Urinary incontinence and overactive bladder. Journal of the Korean Medical Association, 2015, 58, 886.	0.1	2
457	Sacral Neuromodulation for Overactive Bladder. , 2018, , 25-46.		2
459	Urinary incontinence and female urology. , 2019, , 129-192.		Ο
460	Morphofunctional changes of the pelvic organs under conditions of stress urinary incontinence and experimental vaginal prolapse. Reproductive Endocrinology, 2019, .	0.0	0
462	Pharmacological Treatment of Urinary Incontinence and Overactive Bladder: The Evidence. , 2021, , 351-363.		Ο
463	Reduced Ca2+ spark activity contributes to detrusor overactivity of rats with partial bladder outlet obstruction. Aging, 2020, 12, 4163-4177.	1.4	1
464	Pharmacologic Approach to Urinary Incontinence and Voiding Disorders. , 2003, , 245-267.		0
466	Trospium chloride: over 20 years of clinical use. Therapy: Open Access in Clinical Medicine, 2006, 3, 215-226.	0.2	0
467	Spezielle Urodynamik der Frau. , 2007, , 161-173.		4

#	Article	IF	CITATIONS
468	Overactive Bladder and Chronic Pelvic Pain Syndrome. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , 179-187.	0.0	0
469	Neurophysiology of lower urinary tract function and dysfunction. Reviews in Urology, 2003, 5 Suppl 8, S3-S10.	0.9	24
470	Large conductance voltage and Ca-activated K channels affect the physiological characteristics of human urine-derived stem cells. American Journal of Translational Research (discontinued), 2017, 9, 1876-1885.	0.0	3
471	Slow development of bladder malfunction parallels spinal cord fiber sprouting and interneurons' loss after spinal cord transection. Experimental Neurology, 2022, 348, 113937.	2.0	7
472	Ophiocordyceps sinensis: a prominent source of bioactive components for alleviating overactive bladder. Life Sciences Medicine and Biomedicine, 2020, 4, .	0.1	1
473	Trypsin-induced elevated contractile responses in a rat model of interstitial cystitis/bladder pain syndrome: Involvement of PAR2 and intracellular Ca2+ release pathways. Life Sciences, 2022, 293, 120359.	2.0	2
474	The TRPM8 channel as a potential therapeutic target for bladder hypersensitive disorders. Journal of Smooth Muscle Research, 2022, 58, 11-21.	0.7	1
475	Hypothyroidism is prevalent among adult women with chronic lower urinary tract symptoms. LUTS: Lower Urinary Tract Symptoms, 2022, 14, 248-254.	0.6	3
478	Comparison of early loosening vs delayed section of mid-urethral slings for postoperative voiding dysfunction. International Urogynecology Journal, 2023, 34, 675-681.	0.7	2
479	Urodynamic classification of patients with symptoms of overactive bladder. Journal of Urology, 2003, 169, 529-33; discussion 533-4.	0.2	20
482	Relevance of dog as an animal model for urologic diseases. Progress in Molecular Biology and Translational Science, 2022, , 35-65.	0.9	5
484	Urgency and urgency incontinence following stress urinary incontinence surgery: A review of evaluation and management. Indian Journal of Urology, 2022, 38, 268.	0.2	3
485	Earth-friendly-assessed UV-spectrophotometric approaches for concurrent determination of mirabegron and solifenacin succinate in different matrices. Sustainable Chemistry and Pharmacy, 2023, 32, 100976.	1.6	4
486	Overview of Diagnosis and Pharmacological Treatment of Overactive and Underactive Bladder Disorders. , 2022, , 1-13.		0
487	Key role for Kv11.1 (etherâ€aâ€goâ€go related gene) channels in rat bladder contractility. Physiological Reports, 2023, 11, .	0.7	3
490	Overview of Diagnosis and Pharmacological Treatment of Overactive and Underactive Bladder Disorders. , 2023, , 207-219.		0
491	Gene Therapy and Overactive Bladder. Current Bladder Dysfunction Reports, 2024, 19, 37-43.	0.2	0